Oppenheimer Maintains Neurocrine Biosciences (NBIX) Outperform Recommendation
- Stock Market Stocks to buy Stocks to sell
admin
- 0
- 1 minute read
Fintel reports that on October 6, 2023, Oppenheimer maintained coverage of Neurocrine Biosciences (NASDAQ:NBIX) with a Outperform recommendation.
:max_bytes(150000):strip_icc():format(jpeg)/GettyImages-1411173624-c572d225369347339d7f260b69f4a476.jpg "Going Back to India to Retire? Read This First")
:max_bytes(150000):strip_icc():format(jpeg)/GettyImages-1485421674-57b52a1dfce24e91b2d52a695b2bdbec.jpg "Why Stocks Generally Outperform Bonds")
:max_bytes(150000):strip_icc():format(jpeg)/GettyImages-1146822134-029315ec9e4d4bf69244ea8ed786337c-f22a003b0a45409282e721f18828b3dd.jpg "4 Must-Watch Movies for Accountants")